INmune Bio to present data from UK patients treated with INKmune

INmune Bi will present data from UK patients with MDS or AML treated with INKmune at the annual American Society for Hematology, ASH, Conference held in New Orleans December 10th – 13th. The poster presents findings from patients who have received INKmune therapy for treatment of their AML/MDS and provides additional information on the biologic changes that occur in the patients’ NK cells after treatment with INKmune. Highlights include: INKmune safely administered to 4 patients without SAE/R. Demonstrable and sustained NK activation in 3 of the 4 patients. Patient 4 had a high level of disease with low numbers of NK cells of which more than half her NK cells were immature. Persistent tumor killing memory-like NK cells in the patient with MDS for more than 100 days. NK activation temporally associated with significant changes in systemic levels of key cytokines including Macrophage Inflammatory Proteins. INKmune activated NK cells show proteomic and metabolomic changes predictive of improved survival in the tumor microenvironment. The Laurel Phase I trial continues to enroll patients in the UK and EU with two new sites in the process of opening recruitment. In addition, the Company is preparing to expand the INKmune program to the US in a solid tumor indication. The Company will make additional announcements regarding the solid tumor target and the timing of the clinical trial. "Presentation of data at the most important hematologic cancer meeting is an honor. We hope this will be the first of many presentations on this promising program," said RJ Tesi, MD, CEO of INmune Bio. "The ability of INKmune primed NK cells to survive and thrive in the hypoxic and immunologically hostile TME is unique. This biology makes a pivot to INKmune treatment of solid tumors an obvious next step in the platform’s growth."